DOCUMENTS

101

 

NOTICES

156

 

 

MOTS CLES

Meta-Analysis Cohort studies Albinism Ankylosing Antibiotic misuse Intensive care Psoriatic arthritis Spondylitis Patient safety Beta-lactam antibiotics Adolescent Apremilast Vigibase® Pharmacoepidemiology Addiction Atopic dermatitis Systematic review Prostate cancer Graft-versus-host disease Endocrine toxicity Cardio-oncology Autoimmunity Artificial intelligence Ustekinumab Immunotherapy Biologic Ethics ArtThese Arthritis Bacterial rhinosinusitis Antimicrobiens Anxiety Etanercept Quality of life Drug reaction Immune checkpoint inhibitors Pharmacovigilance COVID-19 Access to care Treatment Glucocorticoids Axial spondyloarthritis Alitretinoin Autoimmune diseases Immune-related adverse events Auto-Diagnostic Sipuleucel-T Abus d'antibiotiques Antimicrobials Biologics Alcohol Anxiété Sacroiliitis Apre-milast Biologic drug Adalimumab Stability Cancer Anti-Bacterial Agents Ankylosing spondylitis Biosimilar Pharmaceuticals Antibiotics Angiotensin receptor blockers Cardiomyopathy Primary adrenal insufficiency Placebo Méta-Analyse Azathioprine Anti-HCV Direct Acting Antivirals DAA Spondyloarthritis Regulatory science Cardiotoxicity Antibiotic resistance Antimicrobial resistance Network meta-analysis Epidemiology Antimicrobial Stewardship Biologic therapy ASDAS Auto-immune hepatitis Aging Pregnancy Accelerometer Adverse side effects Psoriasis Acute Myeloid Leukaemia AML Infliximab Management Atrial fibrillation Pharmaco-Épidémiologie Anticancer drugs Biological Therapy BTK protein Anti-TNF Bacterial Drug survival Arrhythmia Angiotensin-converting enzyme inhibitors Dermatology Amyloidosis

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS